Pruritus - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 123
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PB72C4E0AA6EN
Leaflet:

Download PDF Leaflet

Pruritus - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Pruritus - Pipeline Review, H2 2016’, provides an overview of the Pruritus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Pruritus
  • The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
  • The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pruritus
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pruritus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Pruritus Overview
Therapeutics Development
Pipeline Products for Pruritus - Overview
Pipeline Products for Pruritus - Comparative Analysis
Pruritus - Therapeutics under Development by Companies
Pruritus - Therapeutics under Investigation by Universities/Institutes
Pruritus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pruritus - Products under Development by Companies
Pruritus - Products under Investigation by Universities/Institutes
Pruritus - Companies Involved in Therapeutics Development
Albireo AB
Alveonix AG
Amorepacific Corporation
Asana BioSciences, LLC
Cara Therapeutics, Inc.
Chugai Pharmaceutical Co., Ltd.
Creabilis SA
ELORAC, Inc.
Faes Farma, S.A.
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
LEO Pharma A/S
Merck & Co., Inc.
NeRRe Therapeutics Ltd
Nippon Shinyaku Co., Ltd.
Patara Pharma, Inc.
Phosphagenics Limited
RDD Pharma Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
Shionogi & Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Teikoku Pharma USA, Inc.
Tioga Pharmaceuticals, Inc.
Trevi Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Pruritus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ax-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ax-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bilastine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-1609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize CB2 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Substance P for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Featured News & Press Releases
Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings
Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting
Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain
Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis
May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845
Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids
Mar 19, 2015: Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board
Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis
Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration
Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus
Aug 06, 2014: Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting
Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Pruritus, H2 2016
Number of Products under Development for Pruritus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2016
Pruritus - Pipeline by Albireo AB, H2 2016
Pruritus - Pipeline by Alveonix AG, H2 2016
Pruritus - Pipeline by Amorepacific Corporation, H2 2016
Pruritus - Pipeline by Asana BioSciences, LLC, H2 2016
Pruritus - Pipeline by Cara Therapeutics, Inc., H2 2016
Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Pruritus - Pipeline by Creabilis SA, H2 2016
Pruritus - Pipeline by ELORAC, Inc., H2 2016
Pruritus - Pipeline by Faes Farma, S.A., H2 2016
Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2016
Pruritus - Pipeline by Hydra Biosciences, Inc., H2 2016
Pruritus - Pipeline by LEO Pharma A/S, H2 2016
Pruritus - Pipeline by Merck & Co., Inc., H2 2016
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H2 2016
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
Pruritus - Pipeline by Patara Pharma, Inc., H2 2016
Pruritus - Pipeline by Phosphagenics Limited, H2 2016
Pruritus - Pipeline by RDD Pharma Ltd., H2 2016
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
Pruritus - Pipeline by Shionogi & Co., Ltd., H2 2016
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Pruritus - Pipeline by Teikoku Pharma USA, Inc., H2 2016
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016
Pruritus - Pipeline by Trevi Therapeutics, Inc., H2 2016
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pruritus - Dormant Projects, H2 2016
Pruritus - Dormant Projects (Contd.1), H2 2016
Pruritus - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Pruritus, H2 2016
Number of Products under Development for Pruritus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Albireo AB
Alveonix AG
Amorepacific Corporation
Asana BioSciences, LLC
Cara Therapeutics, Inc.
Chugai Pharmaceutical Co., Ltd.
Creabilis SA
ELORAC, Inc.
Faes Farma, S.A.
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
LEO Pharma A/S
Merck & Co., Inc.
NeRRe Therapeutics Ltd
Nippon Shinyaku Co., Ltd.
Patara Pharma, Inc.
Phosphagenics Limited
RDD Pharma Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
Shionogi & Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Teikoku Pharma USA, Inc.
Tioga Pharmaceuticals, Inc.
Trevi Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Skip to top


Pruritus - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 117 pages
Female Contraception - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 73 pages
Insomnia - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 88 pages

Ask Your Question

Pruritus - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: